MedTrace Logo

Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment

NCT02105168 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2200

Last updated 2016-06-10

No results posted yet for this study

Summary

Lung Cancer and melanoma relapsed frequently whereas its very sensitive to treatment such as chemotherapy or radiotherapy. The purpose of this study is to have a better understanding of why those patients are relapsing using next generation sequencing to identify rare mutations and assessed their predictive value.

Conditions

Interventions

PROCEDURE

Blood sample

Optional

PROCEDURE

Tumorous biopsy

Optional

PROCEDURE

Healthy material sample

Optional

Sponsors & Collaborators

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Principal Investigators

  • Benjamin Besse, MD · Gustave Roussy, Cancer Campus, Grand Paris

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02105168 on ClinicalTrials.gov